|
BioScreening - organic compounds for screening
Biotech & Pharma Business and Investment NewsLigand and GlaxoSmithKline Collaboration Identifies New Lead Compound - SAN DIEGO, Mar 30, 2009 (BUSINESS WIRE) —-Ligand Pharmaceuticals Incorporated (NASDAQ: LGND: 2.98, -0.14, -4.49%) today
announced that it has identified a new lead for advancement in its
alliance with GlaxoSmithKline (NYSE:GSK). This newly identified lead
compound is from a program being evaluated as a potential treatment for
[...]
Ligand and GlaxoSmithKline Collaboration Identifies New Lead Compound - SAN DIEGO, Mar 30, 2009 (BUSINESS WIRE) —-Ligand Pharmaceuticals Incorporated (NASDAQ: LGND: 2.98, -0.14, -4.49%) today announced that it has identified a new lead for advancement in its alliance with GlaxoSmithKline (NYSE:GSK). This newly identified lead compound is from a program being evaluated [...]
GTCbio Announces its 4th Annual Assay Development and Screening Technologies Conference taking place - The goal of the 4th annual Assay and Screening Technologies Conference is to provide a forum for academics and professionals in the drug discovery industry to stay abreast of exciting new developments in assay technologies while exchanging ideas and developing more efficient approaches to the drug discovery and development process.
[USPRwire, Thu Mar 26 2009] [...]
European Molecular Biology Laboratory (EMBL) Signs Agreement to License Themis and Surflex-Dock Technologies from Tripos - ST. LOUIS, Mo.–(BUSINESS WIRE)–Triposâ„¢, a leading provider of drug discovery informatics products and services, today announced an agreement with the European Molecular Biology Laboratory (EMBL), Europe’s leading research institution for molecular biology, to license [...]
20 Emerging Healthcare Stocks to Watch in ‘09 - Emerging Diagnostic Index: Average loss of 63.2%, including 39 companies with average market cap of $50M
Emerging Bio-Pharma Index: Top 40 Rated Companies
Emerging Bio-Pharma Index: 36 Additional Companies
Micro-Cap Bio-Pharma Index: 130 companies with an average loss of 43.6% in past year and average market cap of $58M
AspenBio Pharma (APPY) – APPY has pending results for the [...]
MorphoSys and Galapagos Enter Alliance to Co-develop Novel Therapeutic Antibodies in Bone and Joint Disease
Company and People Notes: Patheon and Solvias Form Alliance; AstraZeneca Appoints Rich Fante President of US Business; More…
InhibOx and the National Foundation for Cancer Research Announce Launch of DrugFinder - Oxford, UK (OBBeC) - InhibOx has announced the launch of a free hit identification service. This new service, according to the announcement, will enable research groups in academia and biotechnology companies to exploit an increasingly important starting point for novel drug discovery, namely, crystal structures of target proteins with an inhibitor bound in the active [...]
Pharma Invests Big in Stem Cells - GSK gives the Harvard Stem Cell Institute $25 million.
Today, the pharma company GlaxoSmithKline (GSK) announced a five-year, $25-million-plus collaborative agreement with the Harvard Stem Cell Institute to develop new methods for screening drugs with stem cells.
“GSK believes stem cell science has great potential to aid the discovery of new medicines by improving the screening, identification, [...]
Why Genentech will say ‘yes’ to Roche - The biotech firm faces burdens that come with age, and the Swiss drug maker looks like a good partner.
NEW YORK (Fortune) — As Genentech’s board weighs Monday’s $43.7 billion merger proposal from Roche, the South San Francisco biotech has one overarching reason to fall deeper into the arms of the Swiss drug maker that already [...]
Genentech confirms buyout offer from Roche; shares rally - NEW YORK (Thomson Financial) - Shares of Genentech Inc. surged to their highest price in more than two years on Monday after the San Francisco-based biotechnology company confirmed its receipt of a buyout offer from Roche.
The shares jumped 14% to $93.09 on Monday on a volume of 8 million shares. The issue’s 30-day volume is [...]
Roche Wants to Buy Genentech — Again - In what could become one of the biggest biotech deals ever, Roche announced this morning that it was offering to pay $43.7 billion for the remaining Genentech (NYSE: DNA) shares it doesn’t already own.
Roche and Genentech have had a long and complicated relationship since the 1980s, after Genentech outlicensed one of its first [...]
Pfizer, Lilly, and Merck & Co. Seed Firm with $39M to Challenge High Attrition Rates in R&D - Pfizer, Eli Lilly, Merck & Co. are investing $39 million to form a company to address the issue of high attrition rates in drug development. The new entity, Enlight Biosciences, has been cofounded by PureTech Ventures and academic researchers.
Enlight will develop technologies in a precompetitive model according to what its founding members require. All three [...]
Genedata and Axxam Announce High Throughput Screening Data Analysis Collaboration - Genedata and Axxam have signed a multi-year contract for the implementation of the Genedata Screener® data analysis and management platform into Axxam’s high throughput screening process.
Genedata, the leading provider of in silico solutions for the pharmaceutical and life science industries, and Axxam, a leading biotechnology research organization offering early-stage discovery research services for the life [...]
Galapagos announces milestone payment of EUR 0.8 million in osteoarthritis alliance with GlaxoSmithKline - Galapagos NV (Euronext: GLPG) announced today that it has reached two new milestones in its multi-year drug discovery alliance with GlaxoSmithKline in osteoarthritis, triggering a payment of EUR 0.8 million from GSK.
In June 2006, GSK’s Center of Excellence for External Drug Discovery (CEEDD) and Galapagos initiated a program to deliver disease-modifying drugs with clinical Proof [...]
AstraZeneca and WuXi PharmaTech extend partnership - AstraZeneca and WuXi PharmaTech are to extend their collaboration in a new three-year deal intended to increase AstraZeneca’s global collection of compounds.
The two pharmaceutical companies have been working together for the past two years in an agreement worth $14 million (£7 million).
Under the new deal, AstraZeneca will design compounds that its partner biotechnology company, which [...]
Rentschler Biotechnologie Announces Cooperation with Boehringer Ingelheim - Laupheim, Germany, Mai 21, 2008 - Rentschler Biotechnologie and Boehringer Ingelheim, both leading companies in biopharmaceutical development and production, have signed a preferred partnership agreement. The cooperation will enable Rentschler Biotechnologie’s clients to gain access to Boehringer Ingelheim’s large-scale mammalian biopharmaceutical production facilities in Biberach, Germany and vice versa, [...]
Chelsea Therapeutics Gains Global Rights to I-3D Portfolio Targeting Autoimmune Disease and Transplant Rejection - CHARLOTTE, N.C., April 8, 2008 (PRIME NEWSWIRE) — Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it has acquired full global rights to the I-3D portfolio of orally active, dihydroorotate dehydrogenase (DHODH) inhibiting compounds for the treatment of autoimmune diseases and transplant rejection.
Following a decision to focus its resources on its immunomodulatory compounds, Active Biotech AB [...]
Health Care’s Silent Spring - As the Intergovernmental Working Group (IGWG) of the WHO prepares to meet and discuss how to best facilitate the expropriation of intellectual property rights (in this case the IPR of pharmaceutical patents) it’s important to consider the unintended consequences — the death of medical innovation.
The global purloiners of patents — led by Jamie Love — [...]
Soon-to-be Laid Off Schering-Plough Employees - As reported in today’s Newark Star-Ledger, Schering-Plough’s New Jersey employees will bear the brunt of Fred Hassan’s plan to fire, terminate, let go with extreme prejudice, 5,500 people in S-P’s workforce:
“Schering-Plough’s chief executive said yesterday the budget ax will fall first and hardest in New Jersey as the drugmaker cuts more than $1 billion in [...]
|
|
